Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.coph.2014.12.014 http://scihub22266oqcxt.onion/10.1016/j.coph.2014.12.014 25645316!ä!25645316 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Opin+Pharmacol 2015 ; 21 (ä): 95-104 Nephropedia Template TP {{tp|p=25645316|t=2015. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence |pdf=|usr=}}{{25645316}} gab.com Text Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence JO: Curr Opin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25645316 #FOAvip Direct stimulation of soluble guanylate cyclase (sGC) is emerging as a potential new approach for the treatment of renal disorders. sGC catalyzes the formation of cyclic guanosine monophosphate (cGMP), deficiency of which is implicated in the pathogenesis of chronic kidney disease (CKD). Therefore, new classes of drugs - sGC stimulators and activators - are being investigated in preclinical models under conditions where nitric oxide is deficient. In preclinical models with different etiologies of CKD, the sGC stimulators BAY 41-2272, BAY 41-8543, BAY 60-4552, riociguat and vericiguat and the sGC activators cinaciguat, ataciguat, BI 703704 and GSK2181236A have shown consistently renoprotective effects. Clinical trials are required to confirm these findings in humans, and to ascertain whether these agents could provide a future alternative to guideline-recommended treatments. Twit Text FOAVip Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence ????Curr Opin Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25645316 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25645316 #FOAvip English Wikipedia <ref>{{Cite pmid|25645316}}</ref> Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence #MMPMID25645316 Stasch JP; Schlossmann J; Hocher B Curr Opin Pharmacol 2015[Apr]; 21 (ä): 95-104 PMID25645316show ga Direct stimulation of soluble guanylate cyclase (sGC) is emerging as a potential new approach for the treatment of renal disorders. sGC catalyzes the formation of cyclic guanosine monophosphate (cGMP), deficiency of which is implicated in the pathogenesis of chronic kidney disease (CKD). Therefore, new classes of drugs - sGC stimulators and activators - are being investigated in preclinical models under conditions where nitric oxide is deficient. In preclinical models with different etiologies of CKD, the sGC stimulators BAY 41-2272, BAY 41-8543, BAY 60-4552, riociguat and vericiguat and the sGC activators cinaciguat, ataciguat, BI 703704 and GSK2181236A have shown consistently renoprotective effects. Clinical trials are required to confirm these findings in humans, and to ascertain whether these agents could provide a future alternative to guideline-recommended treatments. |Animals[MESH] |Guanylate Cyclase/*metabolism[MESH] |Kidney/*metabolism[MESH] |Morpholines/pharmacology[MESH] |Pyrazoles/pharmacology[MESH] |Pyridines/pharmacology[MESH] |Pyrimidines/pharmacology[MESH] |Receptors, Cytoplasmic and Nuclear/*metabolism[MESH] |Renal Insufficiency, Chronic/metabolism[MESH]Renal effects of soluble guanylate cyclase stimulators and activators:(epmc).pdf DeepDyve Pubget Overpricing